OBJECTIVE: To determine whether microRNAs (miRNAs) are differentially expressed in human leiomyoma versus matched myometrial tissue. DESIGN: Microarray with real-time polymerase chain reaction (PCR) validation. SETTING: Academic medical center. PATIENT(S): Premenopausal subjects (n = 15), who were undergoing hysterectomies for leiomyoma-related symptoms. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Statistically differential expression of miRNAs in leiomyoma versus myometrium. RESULT(S): Forty-six miRNA species were differentially expressed in leiomyoma versus normal myometrium. Of these, 19 were overexpressed and 27 were underexpressed in leiomyomas. The changes ranged from 1.2-fold to 11.8-fold. These findings were confirmed using real-time reverse transcriptase PCR for selected miRNAs (miRNAs 21, 34a, 125b, 139, and 323). CONCLUSION(S): Our findings indicate that miRNAs are differentially expressed between human leiomyoma and matched myometrium. Given this differential expression, miRNAs may play a role in the pathogenesis of uterine leiomyoma and may serve as future therapeutic targets for the treatment of these tumors.
OBJECTIVE: To determine whether microRNAs (miRNAs) are differentially expressed in humanleiomyoma versus matched myometrial tissue. DESIGN: Microarray with real-time polymerase chain reaction (PCR) validation. SETTING: Academic medical center. PATIENT(S): Premenopausal subjects (n = 15), who were undergoing hysterectomies for leiomyoma-related symptoms. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Statistically differential expression of miRNAs in leiomyoma versus myometrium. RESULT(S): Forty-six miRNA species were differentially expressed in leiomyoma versus normal myometrium. Of these, 19 were overexpressed and 27 were underexpressed in leiomyomas. The changes ranged from 1.2-fold to 11.8-fold. These findings were confirmed using real-time reverse transcriptase PCR for selected miRNAs (miRNAs 21, 34a, 125b, 139, and 323). CONCLUSION(S): Our findings indicate that miRNAs are differentially expressed between humanleiomyoma and matched myometrium. Given this differential expression, miRNAs may play a role in the pathogenesis of uterine leiomyoma and may serve as future therapeutic targets for the treatment of these tumors.
Authors: Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub Journal: Nature Date: 2005-06-09 Impact factor: 49.962
Authors: William H Catherino; Phyllis C Leppert; Matthew H Stenmark; Mark Payson; Clariss Potlog-Nahari; Lynnette K Nieman; James H Segars Journal: Genes Chromosomes Cancer Date: 2004-07 Impact factor: 5.006
Authors: Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq Journal: Mol Cancer Date: 2006-06-19 Impact factor: 27.401
Authors: James H Segars; Estella C Parrott; Joan D Nagel; Xiaoxiao Catherine Guo; Xiaohua Gao; Linda S Birnbaum; Vivian W Pinn; Darlene Dixon Journal: Hum Reprod Update Date: 2014-01-08 Impact factor: 15.610
Authors: Chad J Creighton; Ashley L Benham; Huifeng Zhu; Mahjabeen F Khan; Jeffrey G Reid; Ankur K Nagaraja; Michael D Fountain; Olivia Dziadek; Derek Han; Lang Ma; Jong Kim; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk; Preethi H Gunaratne Journal: PLoS One Date: 2010-03-10 Impact factor: 3.240